[go: up one dir, main page]

MX2018007392A - Polipeptidos para inhibir la activacion del complemento. - Google Patents

Polipeptidos para inhibir la activacion del complemento.

Info

Publication number
MX2018007392A
MX2018007392A MX2018007392A MX2018007392A MX2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A MX 2018007392 A MX2018007392 A MX 2018007392A
Authority
MX
Mexico
Prior art keywords
polypeptides
complement activation
inhibiting complement
effector domain
convertase
Prior art date
Application number
MX2018007392A
Other languages
English (en)
Inventor
Michelfelder Stefan
HÄFFNER Karsten
Original Assignee
Greenovation Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Greenovation Biotech Gmbh filed Critical Greenovation Biotech Gmbh
Publication of MX2018007392A publication Critical patent/MX2018007392A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a un polipéptido que comprende un dominio efector de C3 convertasa, un dominio efector de C5 convertasa y opcionalmente un dominio efector inhibidor del complejo terminal que es resistente a la desregulación por medio de Proteínas FHR fisiológicas y tiene un motivo de dimerización, y a su uso terapéutico.
MX2018007392A 2015-12-23 2016-12-23 Polipeptidos para inhibir la activacion del complemento. MX2018007392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102015016665 2015-12-23
PCT/EP2016/082614 WO2017109208A1 (en) 2015-12-23 2016-12-23 Polypeptides for inhibiting complement activation

Publications (1)

Publication Number Publication Date
MX2018007392A true MX2018007392A (es) 2018-08-15

Family

ID=57838331

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007392A MX2018007392A (es) 2015-12-23 2016-12-23 Polipeptidos para inhibir la activacion del complemento.

Country Status (18)

Country Link
US (2) US10640540B2 (es)
EP (1) EP3394089B1 (es)
JP (2) JP6771568B2 (es)
KR (1) KR20180091097A (es)
CN (1) CN108699121B (es)
AU (1) AU2016375183B2 (es)
CA (1) CA3009393C (es)
DK (1) DK3394089T3 (es)
ES (1) ES2895256T3 (es)
HR (1) HRP20211608T1 (es)
HU (1) HUE056019T2 (es)
IL (1) IL260182B2 (es)
LT (1) LT3394089T (es)
MX (1) MX2018007392A (es)
PL (1) PL3394089T3 (es)
PT (1) PT3394089T (es)
SI (1) SI3394089T1 (es)
WO (1) WO2017109208A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020002185A (es) * 2017-08-31 2020-07-14 Novartis Ag Nuevos usos de derivados de piperidinil-indol.
MA50280A (fr) 2017-09-11 2020-07-22 Insideoutbio Inc Procédés et compositions pour améliorer l'immunogénicité de tumeurs [
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
DE102018120016B4 (de) * 2018-08-16 2020-09-03 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e.V. -Hans-Knöll-Institut- Modulatoren der Funktion von Faktor H-verwandtem Protein 1 und deren Verwendungen in der Kontrolle von Entzündung
CA3180829A1 (en) 2020-05-18 2021-11-25 Novartis Ag Crystalline form of lnp023
US11951101B2 (en) 2020-07-16 2024-04-09 Novartis Ag Methods of using factor B inhibitors
WO2025103318A1 (zh) * 2023-11-13 2025-05-22 沈阳三生制药有限责任公司 一种靶向C3b的双功能融合蛋白及其制备方法与用途
WO2025109172A1 (en) * 2023-11-24 2025-05-30 Universität Ulm Complement modulator
EP4559472A1 (en) * 2023-11-24 2025-05-28 Universität Ulm Complement modulator
LU103244B1 (en) 2024-02-14 2025-08-14 Univ Hamburg Eppendorf Uke Deletion of the mouse homolog of human FHR1 (FHRE) protects ApoE-/- mice from atherosclerosis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0097440B1 (en) * 1982-06-14 1986-09-24 The Upjohn Company Method and kit for removing and assaying complement system fragments
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
ZA200807620B (en) * 2006-03-08 2009-12-30 Archemix Corp Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
EP2894166A1 (en) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2473186A4 (en) 2009-08-31 2013-07-10 Ibc Pharmaceuticals Inc BIS SPECIFIC IMMUNOZYTOKIN DOCK-AND-LOCK COMPLEXES AND THERAPEUTIC USE THEREOF
WO2011156356A1 (en) * 2010-06-09 2011-12-15 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
EP3287142B1 (en) * 2011-04-08 2021-08-04 University Of Leicester Methods for treating conditions associated with masp-2 dependent complement activation
CN102978204B (zh) * 2011-11-11 2018-06-08 张康 Cfhr1基因型、高密度脂蛋白上cfhr1及氧化磷酸胆碱的测定试剂盒及测定方法
US9540626B2 (en) * 2012-03-19 2017-01-10 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
FR3015484A1 (fr) * 2013-12-20 2015-06-26 Lab Francais Du Fractionnement Proteines recombinantes possedant une activite de facteur h
WO2020041644A1 (en) * 2018-08-22 2020-02-27 Alexion Pharmaceuticals, Inc. Fusion proteins and methods of treating complement dysregulation using the same
GB2583560A (en) * 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US20220220169A1 (en) * 2019-05-15 2022-07-14 Insideoutbio, Inc. Modular Therapeutics for the Treatment of Inflammatory Diseases and Cancer
US20210371534A1 (en) * 2020-06-01 2021-12-02 Musc Foundation For Research Development Recombinant Fusion Proteins Targeting P-selectin, and Methods of Use Thereof for Treating Diseases and Disorders

Also Published As

Publication number Publication date
AU2016375183B2 (en) 2021-01-21
IL260182A (en) 2018-07-31
AU2016375183A1 (en) 2018-07-19
BR112018012844A2 (pt) 2018-12-04
JP2019508022A (ja) 2019-03-28
JP2020167999A (ja) 2020-10-15
HRP20211608T1 (hr) 2022-01-21
PT3394089T (pt) 2021-11-03
JP6771568B2 (ja) 2020-10-21
US10640540B2 (en) 2020-05-05
CN108699121A (zh) 2018-10-23
PL3394089T3 (pl) 2022-01-17
DK3394089T3 (da) 2021-11-01
CN108699121B (zh) 2023-07-04
EP3394089A1 (en) 2018-10-31
WO2017109208A1 (en) 2017-06-29
US20200277347A1 (en) 2020-09-03
US11591378B2 (en) 2023-02-28
HUE056019T2 (hu) 2022-01-28
EP3394089B1 (en) 2021-07-28
IL260182B1 (en) 2023-08-01
IL260182B2 (en) 2023-12-01
LT3394089T (lt) 2021-11-25
CA3009393A1 (en) 2017-06-29
ES2895256T3 (es) 2022-02-18
SI3394089T1 (sl) 2021-12-31
CA3009393C (en) 2023-08-22
US20190300589A1 (en) 2019-10-03
KR20180091097A (ko) 2018-08-14

Similar Documents

Publication Publication Date Title
MX2018007392A (es) Polipeptidos para inhibir la activacion del complemento.
IL275333A (en) Inhibitors of fibroblast activation protein
MX2020013881A (es) Compuestos inhibidores de bcl-xl y conjugados de anticuerpo-farmaco que los incluyen.
IL273813A (en) A bleeding stop valve is peeling off
NZ742742A (en) Compositions and methods for inhibiting arginase activity
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
MX2018002899A (es) Tratamiento de retinitis pigmentosa.
PH12015501983B1 (en) Peptides and compositions for treatment of joint damage
MX2019007152A (es) Peptido novedoso.
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
GB201801315D0 (en) Novel dissymmetric n, n-dialkylamides, the snythesis thereof and uses of same
MX2020006510A (es) Peptido novedoso.
PH12017502028A1 (en) Vortioxetine pyroglutamate
MX2017012654A (es) Variantes de protoxina-ii y metodos de uso.
EP3111951A4 (en) Anticancer functional peptide for inhibiting proliferation of cancer stem cell, and use thereof
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
GB2560300B (en) Arc splitter plate
IL261687B (en) Switching valve
EP3461832A9 (en) CLICK CHEMISTRY LIGATION
MX2017007740A (es) Peptido c-terminal de acetilcolinesterasa ciclico en el tratamiento o la prevencion de cancer o metastasis.
NZ719451A (en) Glucagon analog for treatment of severe hypoglycemia
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
MX2016014255A (es) Producto ceramico refractario.
IN2014MU00495A (es)
WO2016040313A3 (en) Methods of treating cancer comprising administering a ppar-gamma agonist